Cai J, Zhang X, Ji Y, Zhang P, She Z, Li H. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res. 2020;126(5):679–704.

Article  PubMed  CAS  Google Scholar 

Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey R, Deaton C, Cuisset T, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.

Article  PubMed  Google Scholar 

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.

Article  PubMed  PubMed Central  Google Scholar 

Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour J, Schattenberg J, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9.

Article  PubMed  Google Scholar 

Zhang XL, Fan JG, Wei L, Shi JP, Zheng MH. Promoting the term MAFLD: China in action. Lancet Gastroenterol Hepatol. 2022;7(7):598.

Article  PubMed  Google Scholar 

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M, Harrison S, Brunt E, Sanyal A. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328–57.

Article  PubMed  Google Scholar 

Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1991.

Article  PubMed  CAS  Google Scholar 

Fouad Y, Elwakil R, Elsahhar M, Said E, Bazeed S, Ali Gomaa A, Hashim A, Kamal E, Mehrez M, Attia D. The NAFLD-MAFLD debate: Eminence vs evidence. Liver International. 2021;41(2):255–60.

Article  PubMed  Google Scholar 

Wang T, George J, Zheng M. Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. Hepatobiliary Surg Nutr. 2021;10(6):849–52.

Article  PubMed  PubMed Central  Google Scholar 

van Kleef L, de Knegt R. The transition from NAFLD to MAFLD: one size still does not fit all—time for a tailored approach? Hepatology. 2022. https://doi.org/10.1002/hep.32552.

Article  PubMed  Google Scholar 

Younossi Z, Rinella M, Sanyal A, Harrison S, Brunt E, Goodman Z, Cohen D, Loomba R. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194–8.

Article  PubMed  Google Scholar 

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).[J] .Dig Liver Dis, 2022,;54:170–182. PMID: 34924319.

Duell P, Welty F, Miller M, Chait A, Hammond G, Ahmad Z, Cohen D, Horton J, Pressman G, Toth P. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the american heart association. Arter Thromb Vasc Biol. 2022. https://doi.org/10.1161/ATV0000000000000153.

Article  CAS  Google Scholar 

Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(10):2138-2147.e2110.

Article  PubMed  Google Scholar 

Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, Targher G, Byrne CD, Yuan WJ, Zheng MH. MAFLD and risk of CKD. Metabolism. 2021. https://doi.org/10.1016/j.metabol.2020.154433.

Article  PubMed  CAS  Google Scholar 

Zheng KI, Sun DQ, Jin Y, Zhu PW, Zheng MH. Clinical utility of the MAFLD definition. J Hepatol. 2021;74(4):989–91.

Article  PubMed  Google Scholar 

Zhang H, Wang Y, Chen C, Lu Y, Wang N. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016. Chin Med J. 2021;134(13):1593–601.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kim H, Lee C, Ahn S, Lee K, Lee B, Baik S, Kim S, Lee J. MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups. Dig Dis Sci. 2022. https://doi.org/10.1007/s10620-022-07508-6.

Article  PubMed  CAS  Google Scholar 

Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, Kokubo Y, Okayama A, Miyamoto Y. Predicting coronary heart disease using risk factor categories for a japanese urban population, and comparison with the Framingham risk score: the suita study. J Atheroscler Thromb. 2016;23(9):1138–9.

Article  PubMed  Google Scholar 

Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, Koseki M, Yoshinaga S, Takahashi H, Anzai K, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115–28.

Article  PubMed  CAS  Google Scholar 

Liu S, Wang J, Wu S, Niu J, Zheng R, Bie L, Xin Z, Wang S, Lin H, Zhao Z, et al. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis. Metabolism. 2021. https://doi.org/10.1016/j.metabol.2021.154779.

Article  PubMed  CAS  Google Scholar 

Liu H, Cao Y, Jin J, Guo Y, Zhu C, Wu N, Gao Y, Xu R, Dong Q, Zheng M, et al. Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. Hep Int. 2021;15(6):1337–46.

Article  Google Scholar 

Noda T, Kamiya K, Hamazaki N, Nozaki K, Ichikawa T, Yamashita M, Uchida S, Maekawa E, Terada T, Reed J, et al. The prevalence of metabolic dysfunction-associated fatty liver disease and its association with physical function and prognosis in patients with acute coronary syndrome. J Clin Med. 2022. https://doi.org/10.3390/jcm11071847.

Article  PubMed  PubMed Central  Google Scholar 

Quek J, Ng CH, Tang ASP, Chew N, Chan M, Khoo CM, Wei CP, Chin YH, Tay P, Lim G, et al. Metabolic associated fatty liver disease increases the risk of systemic complications and mortality a meta-analysis and systematic review of 12 620 736 individuals. Endocr Pract. 2022;28(7):667–72.

Article  PubMed  Google Scholar 

Alexander M, Loomis A, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ. 2019;367: l5367.

Article  PubMed  PubMed Central  Google Scholar 

Wu M, Zha M, Lv Q, Xie Y, Yuan K, Zhang X, Liu X. Non-alcoholic fatty liver disease and stroke: a Mendelian randomization study. Eur J Neurol. 2022;29(5):1534–7.

Article  PubMed  Google Scholar 

George J, Gish RG, Geier A. MAFLD and cardiovascular events: what does the evidence show? Clin Gastroenterol Hepatol. 2021;19(10):2025–8.

Article  PubMed  Google Scholar 

Niriella M, Ediriweera D, Kasturiratne A, De Silva S, Dassanayaka A, De Silva A, Kato N, Pathmeswaran A, Wickramasinghe A, de Silva H. Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study. PLoS ONE. 2021;16(2): e0245762.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172-2181.e2176.

Article  PubMed  Google Scholar 

Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284–91.

Article  PubMed  CAS  Google Scholar 

Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, Wang X, Zhu Y. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082–9.

Article  PubMed  Google Scholar 

Mantovani A, Csermely A, Tilg H, Byrne C, Targher G. Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals. Gut. 2022. https://doi.org/10.1136/gutjnl-2022-328224.

Article  PubMed  Google Scholar 

Davis TME. Diabetes and metabolic dysfunction-associated fatty liver disease. Metabolism. 2021. https://doi.org/10.1016/j.metabol.2021.154868.

Article  PubMed  CAS  Google Scholar 

Zhang Y, Lyu Z, Ma B, Li L, Wang W, Sheng C, Dai H, Huang Y, Song F, Song F, et al. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population. Hep Intl. 2022;16(4):835–45.

Article  Google Scholar 

Caussy C, Aubin A, Loomba R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr DiabRep. 2021;21(5):15.

Google Scholar 

Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, Wang X, Zhu Y. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082–9.

Article  PubMed  Google Scholar 

Lee KK, Stelzle D, Bing R, Anwar M, Strachan F, Bashir S, Newby DE, Shah JS, Chung MH, Bloomfield GS, et al. Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. Lancet Gastroenterol Hepatol. 2019;4(10):794–804.

Article  PubMed  PubMed Central